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Background: Infants with atopic eczema have an increased risk of impaired growth, but the 
origin of this impairment is unclear. The aim of this study was to examine fetal and infant growth 
in relation to infantile atopic eczema.
Methods: Within the UK Southampton Women’s Survey, 1,759 infants with known maternal 
menstrual data had anthropometric measurements at 11, 19, and 34 weeks’ gestation, birth, and 
ages 6 and 12 months, enabling derivation of growth velocity SD scores. Infantile atopic eczema 
at ages 6 and/or 12 months was ascertained using modified UK Working Party diagnostic criteria.
Results: Expressed per SD increase, higher femur length and abdominal circumference at 
34 weeks’ gestation were associated with decreased risks of atopic eczema (eczema OR/SD 
increase 0.81 [95% CI 0.69–0.96], P=0.017 and 0.78 [95% CI 0.65–0.93], P=0.006, respectively), 
while every SD increase in head to abdominal circumference ratio (indicating disproportionate 
growth) was associated with an increase in risk of atopic eczema (1.37 [1.15–1.63], P=0.001). 
Lower velocities of linear growth from 11 weeks’ gestation to birth and birth to age 6 months 
were associated with atopic eczema (atopic eczema OR/SD increase 0.80 [0.65–0.98], P=0.034 
and 0.8 [1 0.66–1.00], P=0.051, respectively). Infants with atopic eczema at age 12 months 
had a larger head circumference in early gestation and faltering of abdominal growth velocity 
from 19  to 34 weeks’ gestation (atopic eczema OR/SD increase 0.67 [0.51–0.88], P=0.003).
Conclusion: Infants with atopic eczema demonstrate altered patterns of fetal growth, including 
faltering of linear growth in utero, prior to the clinical onset of atopic eczema. These findings 
suggest growth falters prior to the start of clinical atopic eczema and its treatment.
Keywords: atopic eczema, fetal growth, infant growth
Introduction
Linear growth impairment in children with atopic eczema is a clinical concern.1–3 
National recommendations in USA,4 UK,5,6 and other settings are that growth is 
monitored as part of clinical care for children with atopic eczema. Possible reasons for 
growth faltering have been proposed and include effects of the inflammatory disease,7 
corticosteroid treatment,8 poor nutrition as a result of an inappropriately restrictive diet,9 
and eczema associated sleep disturbance.10 Hitherto, little attention has been paid to the 
possibility of premorbid changes in growth trajectory in infants with atopic eczema. 
Any such changes in premorbid growth may help explain the growth impairment in 
children with atopic eczema while also providing insights into etiology of the skin 
disorder. The development of inflammatory diseases such as atopic eczema is influenced 
by both genetic determinants and environmental exposures in early life, including poor 
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nutrition,11,12 maternal stress,13,14 smoking,15 and microbiome-
related exposures.16 With increasing evidence that atopic 
disease is partly determined by the fetal environment, better 
understanding of early life environment becomes crucial for 
identifying potential preventative strategies.
Studies examining infant birthweight in relation to atopic 
eczema have been inconsistent,17,18 and it is now recognized 
that infant birthweight is only a crude proxy for patterns of 
fetal growth, which may show stronger associations with 
later outcomes than cross-sectional assessments of size at 
single time points.19 A previous study reported that fetuses 
with below average crown-rump length at 11 weeks gesta-
tion and an above average biparietal diameter at 19 weeks’ 
gestation were more likely to have eczema ascertained by 
postal questionnaire at age 10 years,20 but no previous study 
has examined longitudinal measures of fetal and infant size 
in relation to infantile atopic eczema. More information is 
available for other atopic outcomes, including evidence that 
a large neonatal head circumference and higher abdominal 
circumference growth velocity between 11 and 19 weeks’ 
gestation have been linked to an increased risk of atopy.19
In this study, we examined fetal and infant anthropometric 
measurements and growth velocities in relation to the risk of 
atopic eczema at ages 6 and 12 months, to look for evidence 
of altered growth prior to the clinical onset of atopic eczema 
which might support a prenatal developmental influence on 
the disorder.
Methods
southampton Women’s survey (sWs)
In the UK SWS, between 1998 and 2002, 12,583 women 
aged 20–34 years who were not pregnant were recruited 
from the general population through general practitioners 
in Southampton, UK. Information on maternal diet, life-
style, socioeconomic status, and body composition was 
collected.21 Women who became pregnant were followed 
up through their pregnancies; ultrasound measurements of 
fetal size were performed at 11, 19, and 34 weeks. A total 
of 3,158 live-born singleton infants were delivered. Further 
anthropometry was performed at birth and at ages 6 and 
12 months. The findings reported here are based on 1,759 
term, live singleton births with no congenital abnormalities, 
who were assessed for atopic eczema at 6 and/or 12 months 
and had fetal and infant anthropometric measurements and 
known maternal menstrual data. Neonatal deaths and infants 
with major congenital anomalies, gestational age <37 weeks, 
and missing atopic eczema data at 6 and/or 12 months were 
excluded from the analyses (Figure S1). All phases of the 
SWS were approved by the Southampton and South West 
Hampshire Local Research Ethics Committee, and parents 
gave written informed consent.
Outcome assessment
Case definition of atopic eczema was based on the UK 
Working Party diagnostic criteria for the definition of atopic 
eczema,22 using information collected by trained research 
nurses who administered a standard questionnaire and ascer-
tained other information required for the diagnostic criteria 
(a combination of history of itchy skin condition and two or 
more of the following: history of involvement of the skin 
creases such as folds of elbows, behind the knees, fronts of 
ankles, cheeks, or around the neck; a history of a general dry 
skin in the last year; and visible flexural eczema or eczema 
involving the cheeks/forehead and outer limbs). All infants 
were assessed for atopic eczema before the age of 2 years, 
thus this UK Working Party criterion was met by all infants 
in the study cohort. However, as the infants were not old 
enough to have developed clearly defined atopic disorders, 
a personal history of atopy was omitted as a criterion.
Fetal and infant anthropometric 
measurements
At 11, 19, and 34 weeks’ gestation, women underwent high-
resolution ultrasound scanning by experienced research staff 
using Kretz Voluson® 730 (GE Kretz Ultrasound, Tiefenbach, 
Austria) or Acuson Sequoia® 512 (Siemens, Erlangen, 
Germany) systems, which was cross-calibrated. Measure-
ments of fetal linear size (crown-rump length at 11 weeks, 
femur length at 19 and 34 weeks), head circumference (at 
11, 19, and 34 weeks), and abdominal circumference (at 
11, 19, and 34 weeks) were made according to an interna-
tionally accepted and validated methodology.23 Postnatal 
anthropometry was performed by trained research nurses 
according to standardized procedures, with each measure-
ment repeated three times and the mean value used for 
analysis. Crown-heel length at birth was measured using a 
neonatometer (Harpenden, Wrexham, UK) and at ages 6 and 
12 months using an infantometer (Seca Ltd, Birmingham, 
UK); head and abdominal circumferences were measured 
using unmarked tapes read off against a metal ruler at birth, 
6, and 12 months.
statistical analyses
Summary statistics are presented as mean (SD) or median 
(IQR) for continuous variables, and percentages for categori-
cal variables.
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As measurements were taken close to but not at the 
exact ages specified, the associations between anthropo-
metric measures and age were modeled using Cole’s LMS24 
in LMSchartmaker,25 to create sex-specific size-for-age 
z-scores. This method provides smooth centile curves to 
potentially skewed data, enabling calculation of z-scores at 
exact ages. The method summarizes the changing distribu-
tion of the anthropometric parameters by age using three 
curves representing the skewness (L), the median (M), and 
the coefficient variation (S). These parameters are all used 
together to create the preferred percentiles. LMS has been 
adopted in many studies and is considered a reliable method 
of smoothing growth curves.26–29
Conditional models of change were built using linear 
regression analysis: thus size z-score at 11 weeks was the 
starting point. Conditional change in z-score from 11 to 
19 weeks was defined as the standardized residuals resulting 
from the linear regression model of z-score at 19 weeks on 
z-score at 11 weeks. The conditional change in z-score from 
19 to 34 weeks was obtained from the standardized residu-
als resulting from regressing z-score at 34 weeks on both 
z-score at 19 weeks and z-score at 11 weeks simultaneously. 
This process was continued for each subsequent time point, 
resulting in independent measures of conditional growth. 
Using the measures of linear size at 11 weeks, birth, and 
6 months, additional conditional growth measures using this 
subset of time points were created: linear size at 11 weeks, 
linear growth from 11 weeks to birth, from birth to 6 months, 
and from 6 to 12 months. Measures of conditional growth 
were mutually uncorrelated and yielded SD scores, enabling 
comparison of relationships between growth in different time 
intervals and risk of atopic eczema at ages 6 and 12 months.
Potential confounding variables were determined 
prior to the analysis using a directed acyclic graph (DAG) 
( Figure S2). DAGs provide a robust and objective means of 
selecting confounders. DAGs are a graphical representation 
of causal effects between variables. Based on prior knowl-
edge and usual convention for the causal effects studied, 
these graphs identify potential confounding variables which 
are then adjusted for multivariate analysis to minimize con-
founding bias.30 Additionally, the graphs identify competing 
exposures that can be adjusted for to improve the precision 
of the model. The resulting factors that were included as 
confounding variables in our analyses were maternal body 
mass index (BMI) at initial assessment, educational attain-
ment (maternal age and parity were also considered, but the 
DAG indicated their inclusion was not appropriate), infant 
gestational age, and breastfeeding duration. Competing 
exposures identified and adjusted for were maternal eczema 
in the 12 months prior to the initial assessment, maternal 
smoking, and infant sex. P<0.05 was considered statistically 
significant. Logistic regression analyses were performed 
(Stata version 14.1; StataCorp LP, College Station, TX, USA) 
to relate fetal and infant anthropometric measures (in SD) and 
growth velocities (in SD) to infant atopic eczema at ages 6 
and 12 months, with results presented as atopic eczema OR 
per SD increase (OR/SD).
Results
Cohort characteristics
Table 1 summarizes maternal, fetal, and infant character-
istics. Among the study group, the mothers’ mean (SD) 
age at their child’s birth was 31.0 (3.7) years, 52.2% were 
primiparous, 11.7% smoked during pregnancy, 6.7% of 
mothers had eczema in the past 12 months, 51.1% of infants 
were male, mean (SD) infant birthweight was 3.52 (0.47) kg, 
and median gestational age at birth was 40.1 weeks (IQR 
39.3–41.0). A total of 1,698 infants were assessed for atopic 
eczema at age 6 months, 9.5% of them had atopic eczema. 
At age 12 months, 1,684 infants were assessed and 10.0% 
had atopic eczema. Table S1 shows the characteristics of the 
1,759 participants in the study group in comparison with 
the overall SWS pregnancy cohort; the study group mothers 
were slightly older at child’s birth, higher proportions were 
primiparous or had attained A level or higher education, and 
smoking was less prevalent.
Univariate (unadjusted) and multivariate (adjusted) analy-
ses of atopic eczema at ages 6 and 12 months in relation to 
fetal and infant size measurements are shown in Table S2. 
Figures 1 and 2 show the ORs of atopic eczema in relation to 
fetal and infant size measurements at ages 6 and 12 months, 
respectively. Postnatal anthropometry showed that infants 
with atopic eczema at 6 months were shorter at age 6 months 
(eczema OR/SD increase 0.78, 95% CI 0.65–0.93, P=0.006) 
and that those with atopic eczema at 12 months were shorter 
at ages 6 and 12 months (eczema OR/SD increase 0.81, 95% 
CI 0.67–0.97, P=0.021 and OR 0.82, 95% CI 0.69–0.98, 
P=0.028, respectively).
associations of fetal size and growth 
velocities with infant atopic eczema at 
age 6 months
At 34 weeks’ gestation, a shorter femur length, smaller 
abdominal circumference, and higher head to abdominal 
circumference ratio were associated with increased risks of 
atopic eczema at age 6 months. Expressed per SD increase, 
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higher femur length and abdominal circumference were 
associated with decreased risks of atopic eczema (eczema 
OR/SD increase 0.81, 95% CI 0.69–0.96, P=0.017 and 0.78, 
95% CI 0.65–0.93, P=0.006, respectively), while every SD 
increase in head to abdominal circumference ratio (indicating 
disproportionate growth) was associated with an increase in 
risk of atopic eczema (1.37, 95% CI 1.15–1.63, P=0.001) 
(Figure 1). Fetal head circumference was not related to infant 
atopic eczema at age 6 months (Figure 1).
A lower velocity of linear growth from 11 weeks’ 
 gestation to birth was associated with atopic eczema at age 
6 months (atopic eczema OR/SD increase 0.80, 95% CI 
0.65–0.98, P=0.034) (Figure 3A); this particularly reflected 
lower linear growth velocity from 11 to 19 weeks’ gestation 
(Table S3). Lower velocity of linear growth from birth to 
6 months also showed a trend toward significance (atopic 
eczema OR/SD increase 0.81, 95% CI 0.66–1.00, P=0.051). 
A lower abdominal circumference growth velocity from 19 
to 34 weeks’ gestation was associated with an increased risk 
of atopic eczema at age 6 months (eczema OR/SD increase 
0.71, 95% CI 0.55–0.92, P=0.009), but there were no associa-
tions with head circumference growth velocities (Table S3).
associations of fetal size and growth 
velocities with infant atopic eczema at 
age 12 months
Infants with atopic eczema at age 12 months had a larger 
head circumference in early pregnancy (at 11 and 19 weeks’ 
gestation eczema OR/SD increase 1.25, 95% CI 1.00–1.56, 
P=0.045 and 1.26, 95% CI 1.05–1.51, P=0.012, respectively), 
faltering of abdominal circumference growth velocity from 
19 to 34 weeks’ gestation (eczema OR/SD increase 0.67 
[0.51–0.88], P=0.003) and a higher head to abdominal cir-
cumference ratio at 34 weeks (eczema OR/SD increase 1.22, 
95% CI 1.03–1.46, P=0.025), with trends toward faltering of 
linear growth velocity from 11 weeks to birth and birth to age 
6 months (eczema OR/SD increase 0.81 [0.66–1.00], P=0.051 
and 0.83 [0.68–1.03], P=0.087, respectively) ( Figure 3B and 
Table S3).
Discussion
We found that infants with atopic eczema at age 6 months 
have faltering of linear growth beginning after 11 weeks’ 
gestation, with a higher head to abdominal circumference 
ratio at 34 weeks’ gestation. Infants with atopic eczema 
at age 12 months had a larger head circumference in early 
pregnancy and faltering of abdominal growth in the second 
half of pregnancy. Postnatally, the infants with atopic eczema 
at ages 6 and 12 months were shorter than infants without 
atopic eczema, but the longitudinal measurements of fetal 
size suggest that this growth faltering commenced prior 
to birth. These associations were robust to adjustment for 
potentially confounding variables, notably maternal age, 
Table 1 Characteristics of the study population
Characteristics Total n %, Median (IQR)  
or mean (SD)
Maternal   
age at child birth (years) 1,759 31.0 (3.7)
a level or higher, n (%) 1,755 1,111 (63.3)
smoking in pregnancy, n (%) 1,698 199 (11.7)
Primiparous, n (%) 1,758 917 (52.2)
Eczema in last 12 months, n (%) 1,585 106 (6.7)
Prepregnancy BMi 1,742 24.1 (21.9–27.4)
Fetal/infant measurements   
linear size (mm)   
11 weeks (Crl) 1,489 53.0 (8.9)
19 weeks (Fl) 1,728 30.7 (2.1)
34 weeks (Fl) 1,747 64.9 (2.7)
Birth (Chl) 1,667 500.7 (18.7)
6 months (Chl) 1,326 675.1 (25.2)
12 months (Chl) 1,592 759.7 (28.7)
head circumference (mm)   
11 weeks 1,123 69.8 (9.1)
19 weeks 1,726 168.4 (8.6)
34 weeks 1,688 317.8 (10.8)
Birth 1,682 351.0 (12.6)
6 months 1,337 440.7 (14.1)
12 months 1,645 468.6 (14.4)
abdominal circumference (mm)   
11 weeks 1,044 55.7 (7.5)
19 weeks 1,718 146.3 (9.0)
34 weeks 1,748 307.7 (15.0)
Birth 1,680 317.9 (20.2)
6 months 1,342 477.3 (32.6)
12 months 1,636 497.2 (33.2)
Infant   
Male, n (%) 1,759 899 (51.1)
gestational age at birth (weeks) 1,759 40.1 (39.3–41.0)
Birthweight (kg) 1,750 3.52 (0.47)
Breast feeding (completed months), 
n (%)
never breast fed
<1
1–3
4–6
7–11
12 or more
1,677
270 (16.1)
330 (19.7)
341 (20.3)
325 (19.4)
266 (15.9)
145 (8.7)
6-month assessment   
age (weeks) 1,731 27.4 (26.1–32.9)
atopic eczema, n (%) 1,698 162 (9.5)
12-month assessment   
age (weeks) 1,684 53.7 (52.6–55.0)
atopic eczema, n (%) 1,683 168 (10.0)
Abbreviations: BMi, body mass index; Crl, crown-rump length; Fl, femur length; 
Chl, crown-heel length.
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Figure 2 size measurements in relation to atopic eczema at age 12 months.
Note: (A) linear size, (B) head circumference, (C) abdominal circumference, and (D) head:abdominal circumference ratio. *Controlling for gestation, sex, breastfeeding, 
maternal BMI, qualification, maternal eczema, and smoking in pregnancy.
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Figure 1 size measurements in relation to atopic eczema at age 6 months.
Notes: (A) linear size, (B) head circumference, (C) abdominal circumference, and (D) head:abdominal circumference ratio. *Controlling for gestation, sex, breastfeeding, 
maternal BMI, qualification, maternal eczema, and smoking in pregnancy.
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BMI, education, smoking in pregnancy, and eczema in the 
12 months prior to the initial assessment at preconception 
and infant sex, and duration of breastfeeding.
Our study presents the first longitudinal data examining 
fetal and infant growth velocities to infant atopic eczema 
at ages 6 and 12 months. Previous studies have generally 
focused on anthropometric measurements at birth or during 
infancy, and have found that they were not related to the 
prevalences of reported eczema or hay fever by the age of 
13 years,31 or to eczema at age 7 years.32 The same infant size 
at birth can be achieved through different patterns of fetal 
growth, and few previous studies have examined patterns of 
fetal growth in relation to atopic outcomes. An increase in 
size between first trimester crown-rump length and second 
trimester biparietal diameter has been associated with higher 
risks of eczema and asthma at age 10 years.20 Pike et al19 
reported that rapid early gestation fetal abdominal growth fol-
lowed by late gestation faltering of abdominal circumference 
Figure 3 linear growth velocities in relation to atopic eczema at ages 6 and 12 months.
Notes: *Controlling for gestation, sex, breastfeeding, maternal BMI, qualification, maternal eczema, and smoking in pregnancy. (A) linear growth velocities in relation to 
atopic eczema at age 6 months. (B) linear growth velocities in relation to atopic eczema at age 12 months.
Abbreviations: Crl, crown-rump length; Fl, femur length; Chl, crown-heel length.
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growth was associated with later atopy at age 3 years, and 
late gestation abdominal growth faltering with atopic wheeze.
Mechanistically, it is known that intrauterine growth 
restriction leads to disproportionate fetal growth and a high 
head to abdominal circumference ratio as a result of “brain 
sparing” responses, which direct nutrient-rich blood to main-
tain brain growth away from truncal organs including the thy-
mus, with potential impact on immune development. Animal 
and human studies have linked fetal and birth anthropometric 
parameters indicative of undernutrition during pregnancy 
with smaller thymic size and impaired thymic develop-
ment.12,33,34 We found that a larger fetal head circumference 
at 11 and 19 weeks’ gestation was linked with a higher risk 
of atopic eczema, with evidence of disproportionate head to 
abdominal circumference at 34 weeks. Therefore, we suspect 
that these growth alterations might influence thymus develop-
ment, resulting in a diminished population of T helper (Th) 
1 lymphocytes, favoring Th2 populations and consequently 
raised serum IgE,35 an immune reaction that is seen in atopic 
eczema and other atopic conditions.36 However, the exact 
mechanisms responsible for the association of altered fetal 
growth with development of atopic eczema are unknown, the 
observation points to involvement of periconception or early 
pregnancy factors in the etiology of infantile atopic eczema. 
The patterns of association between anthropometric measure-
ments and infant atopic eczema at ages 6 and 12 months 
differed; this could reflect a chance finding or heterogeneity 
in the etiology and pathogenesis of atopic eczema in early 
childhood.37
Hitherto, it has been thought most likely that the chronic 
inflammatory process associated with atopic eczema results 
in growth impairment as proinflammatory cytokines such as 
IL-6, which promotes Th2 differentiation and simultaneously 
inhibits Th1, can act at the level of the growth plate, or may 
alter the growth hormone insulin-like  growth factor 1 (IGF-
1) axis.7 Animal studies show growth impairment in juvenile 
chronic arthritis and chronic inflammatory bowel disease 
independent of nutrition as a result of an IL-6-mediated 
decrease in IGF-1.38,39 Alternatively, it has been proposed that 
infants with atopic eczema may be susceptible to postnatal 
growth impairment due to treatment of the condition with 
topical or systemic corticosteroids,8 poor nutrition as a result 
of an inappropriately restrictive diet,9 and associated distur-
bance in sleep.10 However, our findings suggest that intrinsic 
and intrauterine factors that influence growth may modify 
the risk of developing atopic eczema as opposed to growth 
faltering developing postnatally as a result of the inflam-
matory skin condition or its treatment. These  findings have 
important clinical implications and suggest that improved 
control of the inflammatory process in infantile atopic eczema 
or avoidance of topical corticosteroids may not necessarily 
resolve the growth impairment seen in many infants with 
atopic eczema.
Strengths of this study are its large sample size, its pro-
spective nature, and the standardized assessment of fetal/
infant size and atopic eczema by trained staff. Only a sub-
sample of the SWS cohort was studied as calculation of fetal 
growth velocities in early gestation requires secure menstrual 
information; otherwise the estimated date of conception has 
to be “set” from a measurement of fetal size in the first half 
of pregnancy, thereby negating the scope for examination of 
early gestation effects. The mother–offspring pairs included 
in the study were therefore those with known menstrual 
data information and consistent ultrasound data, allowing 
for accurate size-for-age fetal and infant measurements and 
calculation of growth velocities. Mothers in the study group 
were slightly older at child’s birth, higher proportions were 
primiparous or had attained A-level or higher education, and 
smoking was less prevalent when compared with the overall 
SWS pregnancy cohort. These factors were considered in the 
DAG, which indicated that maternal education and smoking 
during pregnancy were potential confounding variables and 
were therefore corrected for the statistical analysis. Numer-
ous potentially confounding factors were considered, and the 
DAG identified those that should be included in the statisti-
cal analyses. This objective method provides a robust means 
of assessing the causal relationship between exposure and 
outcome. Residual confounding cannot, however, be com-
pletely excluded. Limitations of the study include the use of 
questionnaire-based assessments for part of the assessment 
for the diagnosis of atopic eczema, which may introduce bias; 
however, the assessment also involved a clinical examination 
undertaken by trained staff. The UK Working Party Diagnostic 
Criteria for Diagnosis of Atopic Dermatitis are highly sensitive 
and specific for identifying cases of atopic eczema, particu-
larly if applied to developed countries;40–44 although they do 
not assess the severity of the disease, they represent the most 
comprehensively validated criteria for the diagnosis of atopic 
eczema, in both community and hospital settings.45,46 The 
criteria were modified to omit atopic disease in a first-degree 
relative from our case definition to avoid too narrow focus 
on familial cases of atopic eczema and to prevent excluding 
an important group of infants from such studies as we were 
seeking to disentangle the apparent heterogeneous phenotypes 
that “atopic eczema” is now thought to represent.34 Maternal 
history of atopic eczema in the 12 months prior to the initial 
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assessment at preconception, however, was considered as a 
confounding variable as determined by the DAG (Figure S2). 
Severity of atopic eczema was not assessed, and it may be 
possible that those with clinically mild atopic eczema may 
not exhibit the same growth impairment as those with a more 
severe condition.10 Although exploratory and hypothesis-
generating methods were used to determine the described 
growth patterns and multiple statistical testing is a potential 
limitation of this study, only three parameters (linear size, 
abdominal circumference, and head circumference) were 
examined to lessen the inherent risks.
Conclusion
Our study demonstrates links between fetal and infant 
anthropometric measurements and growth patterns with risk 
of atopic eczema at ages 6 and 12 months. The findings sug-
gest that growth falters prior to the onset of the inflammatory 
process associated with atopic eczema or its treatment and 
provide additional support for important prenatal influences 
on this skin condition.
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Supplementary materials
Figure S1 selection of study group sample from the southampton Women’s survey (sWs) cohort.
Note: *non assisted conception, regular cycle, sure/certain of last menstrual period (lMP), not on oral contraceptive pill prior to lMP, dating range scan data available, lMP 
consistent with date of conception, first positive pregnancy test, scan data, and gestation at birth.
3,158 Total SWS live singleton births  
8 Neonatal death  
7 Major congenital abnormality 
215 Gestational age <37 weeks 
114 Missing eczema data at 6 and/or 12 months  
2,814 Live singleton, term, no congenital abnormalities, no neonatal death, no missing 
eczema data 
1,055 Uncertain menstrual data and/or discrepant or missing scan data  
1,759 Known menstrual data and consistent scan data* 
Figure S2 Fetal and infant growth and atopic eczema Dag.
Notes: Confounding variables: maternal BMi, maternal education, gestational age, and breastfeeding duration. Competing exposures (variables adjusted for to improve 
precision of model): maternal eczema, smoking during pregnancy, and infant sex.
Abbreviations: BMi, body mass index; Dag, directed acyclic graph.
Infant sex
Gestational age
Breastfeeding duration
Maternal eczemaSmoking during pregnancy
Maternal education
Maternal BMI
Exposure
Outcome
Adjustad variable
Other variable
Maternal age
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Fetal/infant growth
Infant atopic eczen
 
Cl
in
ica
l E
pi
de
m
io
lo
gy
 d
ow
nl
oa
de
d 
fro
m
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
12
8.
24
0.
22
5.
18
 o
n 
04
-M
ar
-2
02
0
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
Clinical Epidemiology 2018:10 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
1861
Faltering of prenatal growth precedes the development of atopic eczema
Table S1 Comparison of the study population with the remainder of the sWs participants
Characteristics Study population 
(n=1,759)
Other SWS participants* 
(n=1,169)
P-value for difference between 
the two groups
Maternal    
age at child’s birth (years) 31.0 (3.7) 30.2 (4.0) <0.001
a level or higher degree (%) 63.3 52.6 <0.001
smoking in pregnancy (%) 11.7 22.3 <0.001
Primiparous (%) 52.2 47.8 0.021
Eczema in the last 12 months (%) 6.7 7.3 0.56
Prepregnancy BMi (kg/m2) 24.1 (21.9–27.4) 24.2 (21.9–27.3) 0.86
Infant    
Male (%) 51.1 52.0 0.65
gestational age (weeks) 40.1 (39.3–41.0) 40.2 (39.2–41.0) 0.71
Birth weight (kg) 3.52 (0.47) 3.49 (0.47) 0.08
Notes: *includes live singleton infants born at term, with no congenital abnormalities and who survived the neonatal period. Values indicate median (iQr), mean (sD), or %.
Abbreviations: sWs, southampton Women’s survey; BMi, body mass index.
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